Ingen appoints director of r&d

Aims to increase sales of in vitro diagnostic (IVD) kits

Ingen Biosciences, a French developer of advanced in vitro diagnostic kits for clinical use, has appointed Karine Mignon-Godefroy as director of research & development.

Mignon-Godefroy joins the firm to generate sales of its first proprietary in vitro diagnostic (IVD) kit. These IVD kits are based on the firm’s specialist knowledge in proteomics and expertise in synthesising new recombinant antigens. Mignon-Godefroy will be responsible for identifying clinically relevant recombinant antigens as potential markers for the detection of infectious diseases found in prosthetic replacements, and to develop innovative IVD kits for clinical use.

‘Dr Mignon-Godefroy’s 15 years’ experience in biotechnology, depth of knowledge and skills will be a major contribution to our on-going r&d efforts,’ said Jean-Pierre Hermet, chief executive of Ingen Biosciences. ‘Her arrival will also strengthen the team, which has made significant inroads into developing products based on innovative technologies.'

Mignon-Godefroy joins Ingen Biosciences from the blood virus division of Bio-Rad, a manufacturer and distributor of products for a range of technologies including proteomics, where she was director of international projects.

You may also like

Manufacturing

Almac highlights SDS-PAGE approach for residual protein determination in new white paper

New white paper explores robust analytical method for residual protein detection in biocatalytic API manufacturing
Manufacturing

Reliable, high-performance pump for HPLC and UHPLC

Biotech Fluidics announce the ASI 540 – an affordable, standalone solvent delivery pump - design optimised for liquid chromatography applications
Regulatory

WHO prequalifies Novartis' antimalarial Coartem Baby for treatment of newborns and young infants

The decision allows global procurement of artemether-lumefantrine (also known as Riamet Baby in some countries) for the first time, with Novartis adding that it will make the treatment available on a largely not-for-profit basis in malaria-endemic regions
Manufacturing

BD and Suttons Creek collaborate to streamline combination product development for pharma and biotech

The new strategic collaboration will help pharmaceutical and biotech companies reduce development risk and regulatory complexity across drug-device combination products, including biologics and GLP-1 therapies
Regulatory

FDA approves AstraZeneca's Saphnelo Pen autoinjector in systemic lupus erythematosus

AstraZeneca has received FDA approval for a once-weekly subcutaneous autoinjector formulation of Saphnelo for systemic lupus erythematosus, offering patients a more convenient alternative to the existing intravenous infusion
You need to be a subscriber to read this article.
Click here to find out more.
Regulatory

UK clinical trial reforms come into force in largest regulatory overhaul in 20 years

The MHRA and Health Research Authority are implementing the most significant package of clinical trial regulatory reforms in more than two decades, introducing faster assessment routes for lower-risk trials and mandatory registration of trial results
Regulatory

FDA grants Orphan Drug Designation to pegrizeprument for prevention of heart transplant rejection

The FDA has granted Orphan Drug Designation to pegrizeprument (VEL-101), a novel monoclonal antibody fragment licensed to Veloxis Pharmaceuticals, for the prevention of heart allograft rejection, following a similar designation granted for liver transplant rejection in January 2026
Subscribe now